<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Cisplatin nephrotoxicity
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Cisplatin nephrotoxicity
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Cisplatin nephrotoxicity
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mark A Perazella, MD, FACP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Didier Portilla, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            A Mazin Safar, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul M Palevsky, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Steven E Schild, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Albert Q Lam, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 22, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          Cisplatin
         </a>
         is a potent and valuable chemotherapy agent used to treat a broad spectrum of malignancies. Renal tubular dysfunction and a cumulative impairment in kidney function, as manifested by a decline in the glomerular filtration rate (GFR), can be dose limiting. The laboratory observation that forced hydration and diuresis may prevent nephrotoxicity facilitated the subsequent clinical development of cisplatin [
         <a href="#rid1">
          1-3
         </a>
         ].
        </p>
        <p>
         Cisplatin-induced kidney toxicity is reviewed here. The use of
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         in patients with preexisting kidney dysfunction and the kidney effects of the platinum analogs,
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         and
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         , are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2834.html" rel="external">
          "Nephrotoxicity of chemotherapy and other cytotoxic agents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1384063032">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple mechanisms contribute to kidney dysfunction following
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         administration. Exposure of tubular cells to cisplatin activates complex signaling pathways that result in tubular cell injury and cell death. A robust inflammatory response, as well as injury to the renal vasculature, results in vasoconstriction, reduced blood flow, and ischemic injury. Collectively, these changes lead to acute kidney injury (AKI) [
         <a href="#rid4">
          4
         </a>
         ]. It is important to note that for many malignancies, cisplatin is used in combination with other drugs that may also be nephrotoxic.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cellular toxicity
         </strong>
         –
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          Cisplatin
         </a>
         (cis-diamminedichloroplatinum II [CDDP]), a platinum compound that is predominantly eliminated through renal clearance. Inside cells, the low chloride concentration facilitates CDDP hydrolysis with generation of charged species. This hydrolysis product is believed to be the active species, reacting with glutathione in the cytoplasm and DNA in the nucleus [
         <a href="#rid5">
          5
         </a>
         ]. In tumors and other dividing cells, cisplatin-DNA intrastrand crosslinks result in cytotoxicity [
         <a href="#rid6">
          6
         </a>
         ]. These molecular events are thought to be responsible for arresting cancer cell proliferation. More than 50 percent of the drug is excreted in the urine in the first 24 hours following cisplatin administration, and the concentration of platinum achieved in the kidney cortex is several fold greater than that in plasma and other organs [
         <a href="#rid7">
          7,8
         </a>
         ]. Cisplatin primarily injures the S3 segment of the proximal tubule, causing a decrease in the glomerular filtration rate (GFR) [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Experimental studies suggest that basolateral drug transporters play a role in
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         uptake [
         <a href="#rid10">
          10
         </a>
         ]. Changes in expression of proximal tubule organic cation transporter 2 (OCT2) have been shown to mediate the accumulation of cisplatin in proximal tubular epithelial cells, which suggests a key role for OCT2 in the development of cisplatin-mediated nephrotoxicity [
         <a href="#rid11">
          11-13
         </a>
         ]. The organic anion transporters OAT1 and OAT3 may also play a role via a mechanism that is independent of OCT2 [
         <a href="#rid14">
          14
         </a>
         ]. In addition, cisplatin uptake may be mediated through the copper transporter protein 1 (Ctr1), which is expressed in basolateral membranes of both proximal and distal tubular cells [
         <a href="#rid15">
          15,16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vasoconstriction
         </strong>
         – Vasoconstriction in the kidney microvasculature appears to contribute to decreased renal blood flow soon after
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         injection, which may lead to ischemic renal tubular injury [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Proinflammatory effects
         </strong>
         –
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          Cisplatin
         </a>
         increases the expression of proinflammatory cytokines, such as tumor necrosis factor (TNA)-alpha, interleukin (IL) 6, interferon (IFN)-gamma, and caspases, which promote the differentiation, maturation, and activation of neutrophils, T cells, and other components of the cellular inflammatory response [
         <a href="#rid19">
          19,20
         </a>
         ]. Experimental models of cisplatin-induced AKI demonstrate increased expression of endothelial cell adhesion molecules and subsequent infiltration of leukocytes and T cells in kidney tissue [
         <a href="#rid21">
          21-23
         </a>
         ]. The potential importance of these mediators was illustrated by the lesser severity of AKI following exposure to cisplatin in mice with defects in these inflammatory pathways [
         <a href="#rid19">
          19,20,24-26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Effects on the proximal tubule
         </strong>
         – The proximal tubule cells are selectively injured by
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         , as manifested by both necrosis and apoptosis, even though nonproliferating cells are generally less sensitive to the toxicity of agents that damage DNA [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Possible reasons for the observed nephrotoxicity of
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         include its enhanced kidney uptake by organic transporters [
         <a href="#rid10">
          10
         </a>
         ], followed by cisplatin-mediated reduced expression and function of sodium-dependent glucose and amino acid transporters [
         <a href="#rid28">
          28
         </a>
         ], reduced expression and function of magnesium and water transporters [
         <a href="#rid7">
          7,8
         </a>
         ], metabolism of cisplatin to glutathione and cysteinyl-glycine conjugates [
         <a href="#rid29">
          29
         </a>
         ], and the generation of reactive oxygen species [
         <a href="#rid30">
          30-36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other cellular effects that have been proposed as the cause of cisplatin-induced nephrotoxicity include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Inhibition of mitochondrial F1F0-ATPase and reduction of mitochondrial oxidative phosphorylation precede apoptotic cell death [
         <a href="#rid37">
          37,38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Induction of hyperlipidemia and the accumulation of triglyceride and nonesterified fatty acids (NEFAs) in kidney tissue, perhaps due to inhibition of fatty acid oxidation in the proximal tubule [
         <a href="#rid38">
          38,39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Significant reduction in messenger RNA (mRNA) levels and enzyme activity of mitochondrial medium chain acyl-CoA dehydrogenase (MCAD).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Possible direct inhibition of peroxisome proliferator-activated receptor (PPAR)-alpha activity in renal epithelial cells [
         <a href="#rid40">
          40,41
         </a>
         ]. This may decrease the expression of PPAR-regulated genes, including those encoding potentially protective fatty acid-binding proteins [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1464923877">
         <span class="h1">
          RISK FACTORS FOR ACUTE KIDNEY INJURY
         </span>
         <span class="headingEndMark">
          —
         </span>
         An increasing risk of acute kidney injury (AKI) is associated with higher doses of
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         that result in high peak plasma free platinum concentrations, previous exposure to cisplatin, preexisting kidney damage, and the concomitant use of other nephrotoxic agents:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          High peak plasma free platinum concentrations
         </strong>
         – High peak plasma free platinum concentrations are associated with an increased risk of AKI, which suggests that the cumulative dose of platinum may play a role in the development of nephrotoxicity. As an example, in a study of 22 patients receiving their first course of
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (50 to 140 mg/m
         <sup>
          2
         </sup>
         ), a peak plasma ultrafiltrable platinum level (free platinum level) in excess of 400 ng/mL was associated with &gt;30 percent decline in creatinine clearance by the fourth course of therapy [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional evidence supporting the importance of high peak plasma platinum concentrations comes from the observation that glomerular filtration rate (GFR) and serum magnesium levels were significantly decreased following
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         administration at doses ≥50 mg/m
         <sup>
          2
         </sup>
         [
         <a href="#rid44">
          44
         </a>
         ]. By comparison, the GFR was maintained in patients receiving cisplatin at a lower daily dose of 20 mg/m
         <sup>
          2
         </sup>
         over five consecutive days [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Previous
         </strong>
         <strong>
          cisplatin
         </strong>
         <strong>
          chemotherapy
         </strong>
         – Patients who have previously been treated with
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         and receive additional cisplatin therapy are at increased risk for developing kidney injury. An increased risk of nephrotoxicity may also be observed when
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         , a less nephrotoxic platinum analog, is used instead of cisplatin in a subsequent-line regimen [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preexisting kidney damage
         </strong>
         – There is an increased risk of AKI with
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         among patients with underlying kidney dysfunction, primarily due to the decreased renal clearance of cisplatin. Cisplatin-based chemotherapy should be used cautiously or avoided in patients with elevated serum creatinine levels. Many of the ongoing national clinical trials exclude patients with creatinine levels &gt;1.5 mg/dL (133 micromol/L) from receiving cisplatin [
         <a href="#rid46">
          46
         </a>
         ]. (See
         <a class="local">
          'Use of cisplatin in patients with kidney impairment'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/2834.html" rel="external">
          "Nephrotoxicity of chemotherapy and other cytotoxic agents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Concomitant use of other nephrotoxic agents
         </strong>
         – The risk of AKI with
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         is increased in patients who are concomitantly receiving potentially nephrotoxic agents, such as aminoglycosides, amphotericin B, and nonsteroidal antiinflammatory drugs.
        </p>
        <p>
        </p>
        <p>
         Other factors that are potentially associated with an increased risk of kidney toxicity include older age, female sex, smoking,
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         dose &gt;100 mg, hypoalbuminemia, history of hypertension, and
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         coadministration [
         <a href="#rid47">
          47-49
         </a>
         ]. The risk related to sex may be due in part to lower unbound cisplatin clearance in females.
        </p>
        <p>
         In adult survivors of childhood cancer, high-dose
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         therapy (cumulative dose &gt;450 mg) has been associated with long-term nephrotoxicity, including lower estimated GFR (eGFR) and albuminuria [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1086275890">
         <span class="h1">
          CLINICAL PRESENTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most important clinical manifestation of
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         nephrotoxicity is kidney injury, which may be acute or chronic. Other kidney manifestations have been described, including electrolyte disturbances, thrombotic microangiopathy, and anemia (due to decreased erythropoietin production).
        </p>
        <p class="headingAnchor" id="H620040972">
         <span class="h2">
          Acute kidney injury
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute kidney injury (AKI) from
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         exposure typically manifests with a slow rise in serum creatinine after five to seven days of therapy. The timing of AKI may be earlier (within three to five days of therapy) in patients with comorbid risk factors, such as preexisting chronic kidney disease (CKD), older age, hypoalbuminemia, or concomitant nephrotoxic drugs. (See
         <a class="local">
          'Risk factors for acute kidney injury'
         </a>
         above.)
        </p>
        <p>
         Most patients will experience a mild to moderate increase in serum creatinine (ie, 1.5 to 2.9 times baseline), while some may progress to more severe AKI (serum creatinine &gt;3.0 times baseline) or require kidney replacement therapy. Severe AKI is uncommon in the absence of preexisting CKD and/or other comorbid risk factors as mentioned above.
        </p>
        <p>
         Unless the kidney injury is severe, the urine output in patients with
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         nephrotoxicity typically remains above 1000 mL per day due to the induction of a concentrating defect. This defect may reflect platinum-induced damage to the loop of Henle, where the countercurrent gradient required for urinary concentration is established, or to the collecting tubules, the site of action of antidiuretic hormone [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         Urinalysis usually shows no or low-grade proteinuria and may have trace amounts of leukocyte esterase; microscopic hematuria is usually absent. The urine sediment may reveal white blood cells, renal tubular epithelial cells, renal tubular epithelial cell casts, and/or granular casts. AKI may be accompanied by tubulopathies, such as a Fanconi-like syndrome, distal renal tubular acidosis, and magnesium and salt wasting, as described below. (See
         <a class="local">
          'Electrolyte disturbances'
         </a>
         below.)
        </p>
        <p>
         Although AKI with
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         can recover within a few weeks after the initial insult, progressive CKD from chronic tubulointerstitial fibrosis and irreversible chronic tubulopathies may develop [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
         The incidence of AKI after
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         administration varies depending upon the dose and frequency of drug administration and the criteria used to define nephrotoxicity. Nephrotoxicity was observed in the initial phase I and phase II studies with cisplatin and was seen in more than 50 percent of cases in some of the early trials prior to the use of intensive hydration regimens [
         <a href="#rid1">
          1,53
         </a>
         ]. More contemporary human studies have reported AKI in approximately 30 percent of adult patients receiving a single dose of cisplatin &gt;50 mg/m
         <sup>
          2
         </sup>
         [
         <a href="#rid54">
          54
         </a>
         ]. A prospective study of children (age &lt;18 years) treated with cisplatin found a similar frequency of AKI among those receiving early (first or second cycle) cisplatin infusions and a lower frequency of AKI (16 percent) among those receiving late (last or second to last cycle) infusions [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
         The incidence and severity of AKI increase with subsequent courses, and kidney damage can eventually become irreversible. As a result, discontinuing therapy with
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         is generally indicated in those who develop evidence of progressive kidney impairment. (See
         <a class="local">
          'Patients with acute kidney injury'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3866927274">
         <span class="h2">
          Electrolyte disturbances
         </span>
        </p>
        <p class="headingAnchor" id="H3375559754">
         <span class="h3">
          Hypomagnesemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypomagnesemia due to urinary magnesium wasting occurs in over one-half of cases of cisplatin-induced nephrotoxicity and can be severe [
         <a href="#rid56">
          56-58
         </a>
         ]. It is dose related and can occur without the presence of concomitant AKI. In patients who receive
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         for several months, urinary magnesium wasting may persist even after discontinuation of cisplatin therapy. In addition to its direct clinical manifestations, hypomagnesemia may exacerbate cisplatin toxicity [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
         The healthy kidney is able to make the urine virtually magnesium free once the plasma magnesium concentration falls below 1.2 mEq/L (1.5 mg/dL or 0.6 mmol/L) [
         <a href="#rid57">
          57
         </a>
         ]. Thus, a fractional excretion of magnesium (FEMg) above 2.5 percent in the presence of hypomagnesemia is indicative of some component of magnesium wasting. A review of magnesium handling and of the different units used to measure the plasma magnesium concentration is available in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/844.html" rel="external">
          "Regulation of magnesium balance"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3087097935">
         <span class="h3">
          Fanconi-like syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cisplatin-mediated nephrotoxicity is accompanied by the development of a Fanconi-like syndrome, with increased urinary excretion of glucose and amino acids (such as alanine, valine, leucine, methionine) and the presence of tricarboxylic acid (TCA) cycle metabolites (lactate and pyruvate) in the urine. In addition to being a marker of tubular damage, glucosuria may also occur due to cisplatin-induced glucose intolerance and hyperglycemia due to abnormal insulin and glucagon responses to a glucose stimulus [
         <a href="#rid38">
          38,60-62
         </a>
         ]. Classic Fanconi syndrome has not been reported, although mild tubular dysfunction may persist [
         <a href="#rid63">
          63
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2327.html" rel="external">
          "Overview and pathophysiology of renal tubular acidosis and the effect on potassium balance", section on 'Proximal (type 2) RTA'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1736130118">
         <span class="h3">
          Distal renal tubular acidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         A distal renal tubular acidosis has been described among patients receiving
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         therapy. In one case series, 4 out of 12 patients who received several courses of cisplatin developed acidifying or concentrating defects despite having normal kidney function [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H814606268">
         <span class="h3">
          Salt wasting
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinically apparent renal salt wasting is a rare manifestation of
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         nephrotoxicity that has been described in case reports and small series [
         <a href="#rid65">
          65-67
         </a>
         ]. Patients typically present with polyuria, hypovolemia, and hyponatremia and, because of similarities in clinical presentation and laboratory findings, may be misdiagnosed with syndrome of inappropriate antidiuretic hormone. Renal salt wasting after cisplatin exposure is usually dose related, although it may occur after even a few doses. Salt wasting usually persists with continued cisplatin exposure and may be permanent despite discontinuation of cisplatin.
        </p>
        <p class="headingAnchor" id="H1593979325">
         <span class="h2">
          Thrombotic microangiopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are rare case reports of thrombotic microangiopathy in patients treated with
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         , either alone [
         <a href="#rid68">
          68
         </a>
         ] or in combination with other anticancer agents such as
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         [
         <a href="#rid69">
          69,70
         </a>
         ] and
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         [
         <a href="#rid71">
          71
         </a>
         ]. This disorder presumably reflects direct vascular injury with secondary platelet activation.
        </p>
        <p>
         The onset of kidney injury may be abrupt or insidious; in the latter setting, it can develop months after treatment has been discontinued. The diagnosis of this form of nephrotoxicity is suggested by the concurrent presence of microangiopathic hemolytic anemia and thrombocytopenia. (See
         <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">
          "Drug-induced thrombotic microangiopathy (DITMA)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1612553473">
         <span class="h2">
          Anemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          Cisplatin
         </a>
         is frequently associated with anemia that is out of proportion to its myelosuppressive effect on the other blood cell lines. Animal and human studies suggest that the renal tubular injury induced by cisplatin results in a deficiency of erythropoietin, which contributes to the anemia [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
         Treatment with erythropoiesis-stimulating agents may be useful in this situation. (See
         <a class="medical medical_review" href="/z/d/html/2799.html" rel="external">
          "Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3491434604">
         <span class="h1">
          USE OF CISPLATIN IN PATIENTS WITH KIDNEY IMPAIRMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          Cisplatin
         </a>
         should be used cautiously in patients with preexisting kidney impairment. There are no definitive studies to help guide the threshold level of kidney function at which cisplatin should not be administered. In our centers, we make every effort to avoid using cisplatin among patients with a serum creatinine concentration &gt;1.5 mg/dL (133 micromol/L) or an estimated glomerular filtration rate (eGFR) of &lt;50 mL/min/1.73 m
         <sup>
          2
         </sup>
         . Possible exceptions are situations in which cisplatin has a proven curative role, such as patients with testicular cancer. (See
         <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">
          "Initial risk-stratified treatment for advanced testicular germ cell tumors"
         </a>
         .)
        </p>
        <p>
         In addition,
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         should be used cautiously in patients with older age (age &gt;60 years), volume depletion, hypoalbuminemia, or poor functional status, and those receiving concomitant nephrotoxic agents [
         <a href="#rid49">
          49,54,73
         </a>
         ]. In such cases,
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         may be a viable alternative, though this will be a matter of judgment that depends, in part, on the extent of data with carboplatin substitution for that particular cancer setting. (See
         <a class="local">
          'Risk factors for acute kidney injury'
         </a>
         above and
         <a class="local">
          'Use of cisplatin analogs'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H570396010">
         <span class="h1">
          PREVENTION OF NEPHROTOXICITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The standard approach to prevent cisplatin-induced nephrotoxicity is the administration of intravenous (IV) isotonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         , avoidance of potential nephrotoxins, and, when appropriate, use of lower doses of
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         . Although a number of pharmacologic agents have been evaluated to decrease nephrotoxicity, none has an established role.
        </p>
        <p class="headingAnchor" id="H1491515502">
         <span class="h2">
          General measures
         </span>
        </p>
        <p class="headingAnchor" id="H1745213306">
         <span class="h3">
          Intravenous saline
         </span>
         <span class="headingEndMark">
          —
         </span>
         The administration of IV
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         to induce a diuresis remains the primary approach for preventing cisplatin-induced nephrotoxicity and must be used in all patients treated with
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         . The optimal hydration solution and regimen to prevent nephrotoxicity associated with cisplatin administration is unclear. We suggest a solution consisting of isotonic saline supplemented with
         <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">
          potassium chloride
         </a>
         and
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         rather than isotonic saline alone or isotonic saline with only potassium chloride. The addition of
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         is generally not required, unless there is evidence of fluid overload.
        </p>
        <p>
         We prepare a solution consisting of 1000 mL of isotonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         plus 20 mEq of
         <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">
          potassium chloride
         </a>
         and 2 grams of
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         . We administer intravenously a minimum of 1000 mL of this solution over two to three hours prior to, and a minimum of 500 mL over the two hours following, the
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         administration. This fluid administration should be adequate to establish a urine flow of at least 100 mL/hour for two hours prior to, and two hours after, chemotherapy administration. The rationale for adding potassium and magnesium to the solution is to avoid the development of hypokalemia and hypomagnesemia that may occur with forced diuresis; in addition, magnesium supplementation may help to limit cisplatin nephrotoxicity [
         <a href="#rid74">
          74,75
         </a>
         ]. Among patients in whom this regimen is contraindicated, alternate chemotherapeutic regimens that do
         <strong>
          not
         </strong>
         include cisplatin should be considered.
        </p>
        <p>
         It is difficult to accurately characterize the effectiveness of IV
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         in preventing
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         nephrotoxicity. This is because, among the trials that have evaluated cisplatin, there were varying definitions of nephrotoxicity, variable cisplatin doses, and patient populations that differed by comorbidity and underlying malignancy. In general, the administration of IV saline with the resultant diuresis significantly lowers the risk of nephrotoxicity. In the initial phase I and II studies, nephrotoxicity was observed in more than 50 percent of cases administered cisplatin [
         <a href="#rid1">
          1,53
         </a>
         ]. It was subsequently observed that the induction of a diuresis using the administration of IV saline dramatically lowered the incidence of nephrotoxicity to very low levels (0 percent in some small, uncontrolled series) [
         <a href="#rid76">
          76
         </a>
         ]. This allowed the development of cisplatin for clinical use [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         There are few randomized trials that have compared different regimens and/or types of IV fluids. In one small pilot trial, 30 adults with head and neck cancer who received low-dose weekly
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         for seven to eight weeks were randomly assigned to prehydration with isotonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         plus
         <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">
          potassium chloride
         </a>
         and
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         or isotonic saline plus only potassium chloride [
         <a href="#rid75">
          75
         </a>
         ]. Although the incidence of cisplatin-associated acute kidney injury (defined as an increase in serum creatinine ≥0.3 mg/dL within seven days) was similar between the groups (1.3 versus 4.6 percent), the incidence of cisplatin-associated acute kidney disease (defined as increase in serum creatinine ≥0.3 mg/dL between the last creatinine measurement and baseline precisplatin creatinine) was lower in the group that received magnesium (7 versus 47 percent, respectively) [
         <a href="#rid75">
          75
         </a>
         ]. A systematic review of 24 studies that examined hydration strategies found that short-duration (over two to six hours), lower-volume (2 to 4 L) hydration with magnesium supplementation in the outpatient setting was effective and safe in preventing cisplatin-induced nephrotoxicity, even in those receiving intermediate- to high-dose cisplatin [
         <a href="#rid74">
          74
         </a>
         ]. However, given the differences in cancer types, cisplatin doses, study types, hydration regimens, and definitions of nephrotoxicity across studies, no definitive conclusions could be made regarding optimal hydration regimens.
        </p>
        <p class="headingAnchor" id="H2521420800">
         <span class="h3">
          Avoidance of potential nephrotoxins
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients receiving
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         , we discontinue medications that may increase the risk for cisplatin nephrotoxicity, including nonsteroidal antiinflammatory drugs, aminoglycosides, and amphotericin B. However, there may be clinical situations in which such medications cannot be discontinued (eg, those that are being used to treat life-threatening conditions). In addition, we try to limit exposure to intravascular iodinated contrast unless it is required for an emergency or life-saving procedure.
        </p>
        <p class="headingAnchor" id="H3787065348">
         <span class="h3">
          Lower doses of cisplatin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lower doses of
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         may help to prevent cisplatin nephrotoxicity, particularly in patients with preexisting kidney impairment or other risk factors for kidney toxicity with cisplatin (see
         <a class="local">
          'Risk factors for acute kidney injury'
         </a>
         above). Consideration of dose reduction should be discussed with the patient's oncologist to determine if this approach may be appropriate without lowering the therapeutic efficacy of cisplatin. Doses of cisplatin are generally not lowered in settings in which cure is the goal of therapy (eg, small cell lung and testicular germ cell tumors).
        </p>
        <p class="headingAnchor" id="H3411636268">
         <span class="h3">
          Use of cisplatin analogs
         </span>
         <span class="headingEndMark">
          —
         </span>
         The less nephrotoxic analog
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         has been substituted for
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         in many chemotherapy regimens (eg, ovarian cancer, non-small cell lung cancer). The relative activity of cisplatin and carboplatin in different diseases needs to be considered in determining whether this is a feasible approach. (See
         <a class="medical medical_review" href="/z/d/html/3239.html" rel="external">
          "First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tube, and peritoneal cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4629.html" rel="external">
          "Subsequent line therapy in non-small cell lung cancer lacking a driver mutation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4156083312">
         <span class="h3">
          Unclear role for mannitol
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          Mannitol
         </a>
         has been used to induce diuresis in patients treated with
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         . However, we do not routinely use mannitol to prevent nephrotoxicity in patients receiving cisplatin, given the lack of clear evidence of benefit. It may be appropriate in select patients, such as those treated with high-dose cisplatin (≥100 mg/m
         <sup>
          2
         </sup>
         ) and/or those with preexisting hypertension [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
         Data evaluating the benefits of
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         are conflicting. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a phase II trial that randomly assigned 48 patients with various solid cancers receiving
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (plus two liters of prehydration) to
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         (20 g) or placebo, there was no significant difference between the groups in the rates of acute kidney injury (AKI; defined using Acute Kidney Injury Network [AKIN] criteria) at 48 hours (30 versus 40 percent, respectively) or seven days (75 versus 80 percent, respectively) after cisplatin [
         <a href="#rid77">
          77
         </a>
         ]. However, compared with patients in the placebo group, fewer patients in the mannitol group had a 24-hour urine creatinine clearance &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         at day 7 (5 versus 36 percent). Univariate analysis suggested that patients receiving &gt;80 mg/m
         <sup>
          2
         </sup>
         of cisplatin gained the greatest benefit from mannitol.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective analysis of 1821 patients with various cancers who received
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         plus prehydration with or without
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         (12.5 or 25 g), use of mannitol was associated with a lower risk of all-grade AKI (driven primarily by a reduction in grade 1 AKI) in patients with gynecologic, upper gastrointestinal, or urinary tract cancers or lymphoma but not in those with head and neck, lung, germ cell, or other cancers [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an observational study that evaluated the addition of
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         (20 g) to standard
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         hydration (1 to 2 liters) in 110 patients with cancer receiving
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         , 14 of the 63 patients (23 percent) who received mannitol plus saline hydration developed AKI (defined by an increase in serum creatinine &gt;0.3 mg/dL) compared with 5 of 47 patients (10 percent) receiving saline hydration only [
         <a href="#rid79">
          79
         </a>
         ]. An increase in serum creatinine &gt;1.5 mg/dL was also more frequent in mannitol treated patients (10 versus 4 percent).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1575627892">
         <span class="h2">
          Approaches we do not use
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Amifostine
         </strong>
         –
         <a class="drug drug_general" data-topicid="8533" href="/z/d/drug information/8533.html" rel="external">
          Amifostine
         </a>
         , an organic thiophosphate, may protect against cisplatin-induced toxicity by donating a protective thiol group, an effect that is highly selective for normal, but not malignant, tissue [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We do
         <strong>
          not
         </strong>
         use
         <a class="drug drug_general" data-topicid="8533" href="/z/d/drug information/8533.html" rel="external">
          amifostine
         </a>
         to prevent cisplatin-induced nephrotoxicity. The principal reasons include the availability of newer regimens that use lower doses of
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         or substitute
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         for cisplatin and the significant toxicity (nausea, vomiting, hypotension) and costs associated with the administration of amifostine. Furthermore, concerns persist about possible interference with the antitumor efficacy of cisplatin. Amifostine should not be used in settings in which chemotherapy can produce a significant survival advantage or chance of cure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Treatment with
         <a class="drug drug_general" data-topicid="8533" href="/z/d/drug information/8533.html" rel="external">
          amifostine
         </a>
         prior to
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         administration decreased nephrotoxicity in animal models and preliminary clinical studies [
         <a href="#rid81">
          81
         </a>
         ]. A phase III trial in women with ovarian cancer found that amifostine reduced the incidence of nephrotoxicity (≥40 percent reduction in creatinine clearance) from 33 to 10 percent with six cycles of a chemotherapy regimen that included cisplatin (100 mg/m
         <sup>
          2
         </sup>
         ) [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         On the basis of these results, the 2002 guidelines from the American Society of Clinical Oncology stated that
         <a class="drug drug_general" data-topicid="8533" href="/z/d/drug information/8533.html" rel="external">
          amifostine
         </a>
         could be considered in patients receiving repeated administrations of
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         for ovarian or non-small cell lung cancer [
         <a href="#rid82">
          82
         </a>
         ], a position that was reiterated in the updated 2008 guidelines, with no new data on which to base a change in the recommendation [
         <a href="#rid83">
          83
         </a>
         ]. However, these studies used higher doses of cisplatin than are typical of contemporary regimens (which almost all use either a single bolus dose of 75 to 80 mg/m
         <sup>
          2
         </sup>
         or, in the setting of a germ cell tumor, a split dose of 20 mg/m
         <sup>
          2
         </sup>
         daily for five days), and there are no data supporting the use of amifostine in other settings. (See
         <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">
          "Initial risk-stratified treatment for advanced testicular germ cell tumors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4633.html" rel="external">
          "Extensive-stage small cell lung cancer: Initial management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other chemoprotective agents
         </strong>
         – Several other approaches have been evaluated to prevent cisplatin-induced nephrotoxicity, including
         <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">
          sodium thiosulfate
         </a>
         [
         <a href="#rid84">
          84,85
         </a>
         ],
         <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">
          N-acetylcysteine
         </a>
         [
         <a href="#rid86">
          86
         </a>
         ],
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         [
         <a href="#rid87">
          87,88
         </a>
         ], glycine [
         <a href="#rid89">
          89
         </a>
         ], peroxisome proliferator-activated receptor (PPAR)-alpha ligand [
         <a href="#rid38">
          38
         </a>
         ], polymeric
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         nanoparticles [
         <a href="#rid90">
          90
         </a>
         ], cell cycle inhibitors [
         <a href="#rid91">
          91
         </a>
         ], and
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         [
         <a href="#rid92">
          92
         </a>
         ]. However, none of these agents have an established role in patients being treated with cisplatin.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3315200321">
         <span class="h1">
          MONITORING FOR NEPHROTOXICITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients who receive
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         therapy should be monitored for the development of nephrotoxicity. In general, patients should have monitoring of serum creatinine and electrolyte levels (including sodium, potassium, magnesium, and phosphorus) following treatment. A urinalysis should also be obtained periodically, especially if there is an increase in serum creatinine concentration. The frequency of monitoring may vary depending upon the clinical scenario and institutional practice. In patients with risk factors for cisplatin nephrotoxicity (see
         <a class="local">
          'Risk factors for acute kidney injury'
         </a>
         above), more frequent monitoring (ie, daily for the first few days after cisplatin administration) may be advisable.
        </p>
        <p class="headingAnchor" id="H3494355330">
         <span class="h1">
          MANAGEMENT OF NEPHROTOXICITY
         </span>
        </p>
        <p class="headingAnchor" id="H2982334772">
         <span class="h2">
          Patients with acute kidney injury
         </span>
         <span class="headingEndMark">
          —
         </span>
         The general approach to the management of acute kidney injury (AKI) after
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         administration is the same as that for other causes of AKI. These issues are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14035.html" rel="external">
          "Overview of the management of acute kidney injury (AKI) in adults"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          Cisplatin
         </a>
         discontinuation is appropriate in patients who develop AKI, particularly those with moderate to severe AKI (increase in serum creatinine to &gt;2.0 times baseline). If the inclusion of cisplatin in the treatment regimen is considered to be life-saving or life-extending, retreatment with cisplatin may be considered after recovery from AKI.
        </p>
        <p class="headingAnchor" id="H780381659">
         <span class="h2">
          Patients with electrolyte disturbances
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, patients with electrolyte disturbances after
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         administration are treated with appropriate supplementation. Discontinuation of cisplatin is not required in this setting, especially if the patient's cancer is being effectively treated with cisplatin or treatment with cisplatin is potentially life-saving or life-extending. However, discontinuation of cisplatin may be necessary if the patient has concurrent AKI or if the electrolyte disturbances are difficult to manage even with aggressive supplementation:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypomagnesemia
         </strong>
         – Treatment of hypomagnesemia generally consists of magnesium supplementation. High doses may be required since raising the plasma magnesium concentration will increase the degree of urinary magnesium wasting. In patients with refractory hypomagnesemia, the addition of a potassium-sparing diuretic such as
         <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">
          amiloride
         </a>
         may be of benefit, although there are no data to support its use in patients with cisplatin-mediated hypomagnesemia. The treatment of hypomagnesemia is discussed elsewhere [
         <a href="#rid93">
          93
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/834.html" rel="external">
          "Hypomagnesemia: Evaluation and treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fanconi-like syndrome
         </strong>
         – Patients who develop proximal tubular dysfunction (Fanconi-like syndrome) after
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         administration should be managed with oral or intravenous (IV) supplementation depending upon the severity of the deficiency. Patients with evidence of a renal tubular acidosis should receive alkali therapy (eg,
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         , sodium citrate,
         <a class="drug drug_general" data-topicid="10225" href="/z/d/drug information/10225.html" rel="external">
          potassium citrate
         </a>
         ) to correct their metabolic acidosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/835.html" rel="external">
          "Hypophosphatemia: Evaluation and treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2297.html" rel="external">
          "Clinical manifestations and treatment of hypokalemia in adults", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2329.html" rel="external">
          "Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis", section on 'Proximal (type 2) renal tubular acidosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Salt wasting
         </strong>
         – Patients with renal salt wasting following
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         should be acutely treated with IV
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         to correct volume depletion and hyponatremia if present. Salt tablets can be administered once the patient is volume repleted and should be dose titrated to symptoms and blood pressure to avoid symptomatic hypotension and hypovolemic hyponatremia.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4053702522">
         <span class="h2">
          Patients with thrombotic microangiopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The specific treatment of thrombotic microangiopathy resulting from
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         and other chemotherapeutic agents is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">
          "Drug-induced thrombotic microangiopathy (DITMA)", section on 'Management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2835477501">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Long-term follow-up of patients exposed to
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         indicates that kidney function either remains stable or improves over time in patients with a glomerular filtration rate (GFR) &gt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         at the end of therapy [
         <a href="#rid94">
          94,95
         </a>
         ]. Whether such improvement reflects an increase in the number of functioning nephrons or hypertrophy of nephrons that remained relatively intact is unclear [
         <a href="#rid96">
          96,97
         </a>
         ].
        </p>
        <p>
         The largest study to evaluate long-term kidney outcomes included 821 adults who received
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         for treatment (cumulative dose range ≤100 to &gt;701 mg/m
         <sup>
          2
         </sup>
         ) across multiple tumor types and survived for at least five years after the initial dose [
         <a href="#rid54">
          54
         </a>
         ]. At baseline, 32 percent of patients had stage 1 chronic kidney disease (CKD), 58 percent had stage 2 CKD, 11 percent had stage 3 CKD, and none had an estimated GFR (eGFR) &lt;29 mL/min/1.73 m
         <sup>
          2
         </sup>
         . Over a median of six years, acute kidney injury (AKI; defined as an increase in serum creatinine of ≥25 percent from baseline) occurred in 31 percent of patients. The following observations were noted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At the completion of
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         therapy, 17 percent had stage 1 CKD, 52 percent had stage 2 CKD, 29 percent had stage 3 CKD, and 2 percent had an eGFR &lt;29 mL/min/1.73 m
         <sup>
          2
         </sup>
         . Progression to a higher stage of CKD occurred in 64 percent of patients with stage 1 CKD, 33 percent of those with stage 2 CKD, and 6 percent of those with stage 3 CKD at baseline.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At year 5 after the first cycle of
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         therapy, 11 percent had stage 1 CKD, 57 percent had stage 2 CKD, 30 percent had stage 3 CKD, and 3 percent had an eGFR &lt;29 mL/min/1.73 m
         <sup>
          2
         </sup>
         . Between years 1 and 5, progression to a higher stage of CKD occurred in 74 percent of patients with stage 1 CKD, 22 percent of those with stage 2 CKD, and 6 percent of those with stage 3 CKD.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2405094279">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110752.html" rel="external">
          "Society guideline links: Acute kidney injury in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1527219272">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General principles
         </strong>
         –
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          Cisplatin
         </a>
         is a potent anticancer agent usually administered in combination with other chemotherapy agents to treat a broad spectrum of malignancies. Cisplatin-induced nephrotoxicity is a dose-limiting side effect, which most commonly is manifested by acute and chronic impairment of kidney function. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – Multiple mechanisms contribute to kidney dysfunction following
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         administration. Exposure of tubular cells to cisplatin activates complex signaling pathways that result in tubular cell injury and cell death. A robust inflammatory response, as well as injury to the renal vasculature, results in vasoconstriction, reduced blood flow, and ischemic injury. Collectively, these changes lead to acute kidney injury (AKI). (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentations
         </strong>
         – The most important clinical manifestation of
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         nephrotoxicity is kidney injury, which may be acute or chronic. Other kidney manifestations have been described, including electrolyte disturbances, thrombotic microangiopathy, and anemia. (See
         <a class="local">
          'Clinical presentations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention of nephrotoxicity
         </strong>
         – A number of measures are potentially useful to prevent acute
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         nephrotoxicity and chronic kidney disease (CKD):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Intravenous
         </strong>
         <strong>
          saline
         </strong>
         <strong>
         </strong>
         – Intravenous (IV) isotonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         is generally administered to all patients before and after
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         therapy to induce a diuresis. The optimal IV solution and regimen is unclear. We suggest a solution consisting of isotonic saline plus
         <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">
          potassium chloride
         </a>
         and
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         rather than isotonic saline alone or isotonic saline with only potassium chloride (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Intravenous saline'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Avoiding nephrotoxins
         </strong>
         – In patients receiving
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         , we discontinue medications that may increase the risk for cisplatin nephrotoxicity, including nonsteroidal antiinflammatory drugs, aminoglycosides, and amphotericin B. We also try to limit exposure to intravascular iodinated contrast unless it is required for an emergency or life-saving procedure. (See
         <a class="local">
          'Avoidance of potential nephrotoxins'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Lower doses of
         </strong>
         <strong>
          cisplatin
         </strong>
         <strong>
         </strong>
         – Lower doses of
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         may help to prevent cisplatin nephrotoxicity, particularly in patients with preexisting kidney impairment or other risk factors for kidney toxicity with cisplatin. Consideration of dose reduction should be discussed with the patient's oncologist to determine if this approach may be appropriate without lowering the therapeutic efficacy of cisplatin. (See
         <a class="local">
          'Lower doses of cisplatin'
         </a>
         above and
         <a class="local">
          'Use of cisplatin analogs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring for nephrotoxicity
         </strong>
         – All patients who receive
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         therapy should be monitored for the development of nephrotoxicity. In general, patients should have monitoring of serum creatinine and electrolyte levels (including sodium, potassium, magnesium, and phosphorus) following treatment. A urinalysis should also be obtained periodically, especially if there is an increase in serum creatinine concentration. The frequency of monitoring may vary depending upon the clinical scenario and institutional practice. (See
         <a class="local">
          'Monitoring for nephrotoxicity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of nephrotoxicity
         </strong>
         – Discontinuation of
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         is appropriate in patients who develop AKI, particularly those with moderate to severe AKI. In general, patients with electrolyte disturbances after cisplatin administration are treated with appropriate supplementation. Discontinuation of cisplatin is not required in this setting, especially if the patient's cancer is being effectively treated with cisplatin or treatment with cisplatin is potentially life-saving or life-extending. However, discontinuation of cisplatin may be necessary if the patient has concurrent AKI or if the electrolyte disturbances are difficult to manage even with aggressive supplementation. (See
         <a class="local">
          'Management of nephrotoxicity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2597433717">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The editorial staff at UpToDate acknowledge Richard T Penson, MD, MRCP, and Melissa L Shannon, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Cvitkovic E, Spaulding J, Bethune V, et al. Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 1977; 39:1357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonzales-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 1977; 39:1362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayes DM, Cvitkovic E, Golbey RB, et al. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 1977; 39:1372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manohar S, Leung N. Cisplatin nephrotoxicity: a review of the literature. J Nephrol 2018; 31:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. (Review). Oncol Rep 2003; 10:1663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galea AM, Murray V. The interaction of cisplatin and analogues with DNA in reconstituted chromatin. Biochim Biophys Acta 2002; 1579:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Litterst CL, Torres IJ, Guarino AM, et al. Plasma levels and organ distribution of platinum in the rat, dog, and dog fish following intravenous administration of cis-DDP (II). J Clin Hematol Oncol 1977; 7:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Safirstein R, Miller P, Guttenplan JB. Uptake and metabolism of cisplatin by rat kidney. Kidney Int 1984; 25:753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dobyan DC, Levi J, Jacobs C, et al. Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther 1980; 213:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urakami Y, Okuda M, Masuda S, et al. Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther 1998; 287:800.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yokoo S, Yonezawa A, Masuda S, et al. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol 2007; 74:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Filipski KK, Loos WJ, Verweij J, Sparreboom A. Interaction of Cisplatin with the human organic cation transporter 2. Clin Cancer Res 2008; 14:3875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi MK, Song IS. Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet 2008; 23:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu S, Leblanc AF, Gibson AA, et al. Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity. Clin Transl Sci 2017; 10:412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishida S, Lee J, Thiele DJ, Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A 2002; 99:14298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pabla N, Murphy RF, Liu K, Dong Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol 2009; 296:F505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luke DR, Vadiei K, Lopez-Berestein G. Role of vascular congestion in cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 1992; 7:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winston JA, Safirstein R. Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am J Physiol 1985; 249:F490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002; 110:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramesh G, Reeves WB. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol 2005; 289:F166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly KJ, Meehan SM, Colvin RB, et al. Protection from toxicant-mediated renal injury in the rat with anti-CD54 antibody. Kidney Int 1999; 56:922.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li S, Gokden N, Okusa MD, et al. Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. Am J Physiol Renal Physiol 2005; 289:F469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu M, Chien CC, Burne-Taney M, et al. A pathophysiologic role for T lymphocytes in murine acute cisplatin nephrotoxicity. J Am Soc Nephrol 2006; 17:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramesh G, Reeves WB. TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 2003; 285:F610.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faubel S, Ljubanovic D, Reznikov L, et al. Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis. Kidney Int 2004; 66:2202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang B, Ramesh G, Norbury CC, Reeves WB. Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int 2007; 72:37.
          </a>
         </li>
         <li class="breakAll">
          Portilla D, Kaushal GP, Basnakian AG. Recent progress in the pathophysiology of acute renal failure. In: Principles of Molecular Medicine, 2nd ed., Runge MS, Patterson C (Eds), Humana Press, Totawa, NJ 2006. p.643.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu EY, Perlina A, Vu H, et al. Integrated pathway analysis of rat urine metabolic profiles and kidney transcriptomic profiles to elucidate the systems toxicology of model nephrotoxicants. Chem Res Toxicol 2008; 21:1548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Townsend DM, Deng M, Zhang L, et al. Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 2003; 14:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baliga R, Ueda N, Walker PD, Shah SV. Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev 1999; 31:971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis CA, Nick HS, Agarwal A. Manganese superoxide dismutase attenuates Cisplatin-induced renal injury: importance of superoxide. J Am Soc Nephrol 2001; 12:2683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masuda H, Tanaka T, Takahama U. Cisplatin generates superoxide anion by interaction with DNA in a cell-free system. Biochem Biophys Res Commun 1994; 203:1175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanaka-Kagawa T, Kitahara J, Seko Y, et al. Reduced sensitivity of HeLa cells to cis-platinum by simultaneous overexpression of copper, zinc-superoxide dismutase and catalase. Biochem Pharmacol 1999; 57:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Appenroth D, Fröb S, Kersten L, et al. Protective effects of vitamin E and C on cisplatin nephrotoxicity in developing rats. Arch Toxicol 1997; 71:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lieberthal W, Triaca V, Levine J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol 1996; 270:F700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGinness JE, Proctor PH, Demopoulos HB, et al. Amelioration of cis-platinum nephrotoxicity by orgotein (superoxide dismutase). Physiol Chem Phys 1978; 10:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nowak G. Protein kinase C-alpha and ERK1/2 mediate mitochondrial dysfunction, decreases in active Na+ transport, and cisplatin-induced apoptosis in renal cells. J Biol Chem 2002; 277:43377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Portilla D, Li S, Nagothu KK, et al. Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int 2006; 69:2194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdel-Gayoum AA, El-Jenjan KB, Ghwarsha KA. Hyperlipidaemia in cisplatin-induced nephrotic rats. Hum Exp Toxicol 1999; 18:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li S, Wu P, Yarlagadda P, et al. PPAR alpha ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity. Am J Physiol Renal Physiol 2004; 286:F572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagothu KK, Bhatt R, Kaushal GP, Portilla D. Fibrate prevents cisplatin-induced proximal tubule cell death. Kidney Int 2005; 68:2680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Negishi K, Noiri E, Sugaya T, et al. A role of liver fatty acid-binding protein in cisplatin-induced acute renal failure. Kidney Int 2007; 72:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reece PA, Stafford I, Russell J, et al. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 1987; 5:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartmann JT, Kollmannsberger C, Kanz L, Bokemeyer C. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 1999; 83:866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siegert W, Beyer J, Strohscheer I, et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol 1994; 12:1223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14:2101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Jongh FE, van Veen RN, Veltman SJ, et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 2003; 88:1199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Jongh FE, Verweij J, Loos WJ, et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 2001; 19:3733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motwani SS, McMahon GM, Humphreys BD, et al. Development and Validation of a Risk Prediction Model for Acute Kidney Injury After the First Course of Cisplatin. J Clin Oncol 2018; 36:682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dekkers IA, Blijdorp K, Cransberg K, et al. Long-term nephrotoxicity in adult survivors of childhood cancer. Clin J Am Soc Nephrol 2013; 8:922.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim SW, Lee JU, Nah MY, et al. Cisplatin decreases the abundance of aquaporin water channels in rat kidney. J Am Soc Nephrol 2001; 12:875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol 2010; 30:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wittes RE, Brescia F, Young CW, et al. Combination chemothereapy with cis-diamminedichloroplatinum (II) and bleomycin in tumors of the head and neck. Oncology 1975; 32:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Latcha S, Jaimes EA, Patil S, et al. Long-Term Renal Outcomes after Cisplatin Treatment. Clin J Am Soc Nephrol 2016; 11:1173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McMahon KR, Rassekh SR, Schultz KR, et al. Epidemiologic Characteristics of Acute Kidney Injury During Cisplatin Infusions in Children Treated for Cancer. JAMA Netw Open 2020; 3:e203639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 1979; 90:929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam M, Adelstein DJ. Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin. Am J Kidney Dis 1986; 8:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sutton RA, Walker VR, Halabe A, et al. Chronic hypomagnesemia caused by cisplatin: effect of calcitriol. J Lab Clin Med 1991; 117:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lajer H, Kristensen M, Hansen HH, et al. Magnesium depletion enhances cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol 2005; 56:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldstein RS, Mayor GH, Rosenbaum RW, et al. Glucose intolerance following cis-platinum treatment in rats. Toxicology 1982; 24:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldstein RS, Mayor GH, Gingerich RL, et al. The effects of cisplatin and other divalent platinum compounds on glucose metabolism and pancreatic endocrine function. Toxicol Appl Pharmacol 1983; 69:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oeffinger KC, Hudson MM. Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors. CA Cancer J Clin 2004; 54:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koch Nogueira PC, Hadj-Aïssa A, Schell M, et al. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. Pediatr Nephrol 1998; 12:572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swainson CP, Colls BM, Fitzharris BM. Cis-platinum and distal renal tubule toxicity. N Z Med J 1985; 98:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hutchison FN, Perez EA, Gandara DR, et al. Renal salt wasting in patients treated with cisplatin. Ann Intern Med 1988; 108:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cao L, Joshi P, Sumoza D. Renal salt-wasting syndrome in a patient with cisplatin-induced hyponatremia: case report. Am J Clin Oncol 2002; 25:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamdi T, Latta S, Jallad B, et al. Cisplatin-induced renal salt wasting syndrome. South Med J 2010; 103:793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilbert RD, Stanley LK, Fowler DJ, et al. Cisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of CD46 treated with eculizumab. Clin Kidney J 2013; 6:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson AM, Rose BD, Graff LG, et al. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 1984; 101:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thurnher D, Kletzmayr J, Formanek M, et al. Chemotherapy-related hemolytic-uremic syndrome following treatment of a carcinoma of the nasopharynx. Oncology 2001; 61:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki Y, Kanazawa K, Kanai R, et al. A case of primary lung squamous cell carcinoma mimicking malignant mesothelioma producing granulocyte colony stimulating factor with chemotherapy (cisplatin and gemcitabine)-associated thrombotic thrombocytopenic purpura (TTP); An autopsy case report. Lung Cancer 2019; 136:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wood PA, Hrushesky WJ. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest 1995; 95:1650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stewart DJ, Dulberg CS, Mikhael NZ, et al. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol 1997; 40:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crona DJ, Faso A, Nishijima TF, et al. A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity. Oncologist 2017; 22:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suppadungsuk S, Phitakwatchara W, Reungwetwattana T, et al. Preloading magnesium attenuates cisplatin-associated nephrotoxicity: pilot randomized controlled trial (PRAGMATIC study). ESMO Open 2022; 7:100351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stark JJ, Howel SB. Nephrotoxicity of cis-platinum (II) dichlorodiammine. Clin Pharmacol Ther 1978; 23:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sainamthip P, Saichaemchan S, Satirapoj B, Prasongsook N. The Effect of Intravenous Mannitol Combined With Normal Saline in Preventing Cisplatin-Induced Nephrotoxicity: A Randomized, Double-Blind, Placebo-Controlled Trial. JCO Glob Oncol 2022; 8:e2100275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bégin AM, Monfette ML, Boudrias-Dalle É, et al. Effect of mannitol on acute kidney injury induced by cisplatin. Support Care Cancer 2021; 29:2083.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rachman A, Wafa S, Nugroho P, Koesnoe S. The effect of mannitol addition to hydration on acute kidney injury event after high dose cisplatin chemotherapy: an ambispective cohort study. BMC Cancer 2022; 22:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castiglione F, Dalla Mola A, Porcile G. Protection of normal tissues from radiation and cytotoxic therapy: the development of amifostine. Tumori 1999; 85:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Capizzi RL. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects. Semin Oncol 1999; 26:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schuchter LM, Hensley ML, Meropol NJ, et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002; 20:2895.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009; 27:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ries F, Klastersky J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 1986; 8:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howell SB, Pfeifle CL, Wung WE, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982; 97:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu YJ, Muldoon LL, Neuwelt EA. The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. J Pharmacol Exp Ther 2005; 312:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heidemann HT, Müller S, Mertins L, et al. Effect of aminophylline on cisplatin nephrotoxicity in the rat. Br J Pharmacol 1989; 97:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benoehr P, Krueth P, Bokemeyer C, et al. Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial. J Am Soc Nephrol 2005; 16:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heyman SN, Spokes K, Egorin MJ, Epstein FH. Glycine reduces early renal parenchymal uptake of cisplatin. Kidney Int 1993; 43:1226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sengupta P, Basu S, Soni S, et al. Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc Natl Acad Sci U S A 2012; 109:11294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pabla N, Gibson AA, Buege M, et al. Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions. Proc Natl Acad Sci U S A 2015; 112:5231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bao H, Ge Y, Wang Z, et al. Delayed administration of a single dose of lithium promotes recovery from AKI. J Am Soc Nephrol 2014; 25:488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bundy JT, Connito D, Mahoney MD, Pontier PJ. Treatment of idiopathic renal magnesium wasting with amiloride. Am J Nephrol 1995; 15:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hansen SW, Groth S, Daugaard G, et al. Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer. J Clin Oncol 1988; 6:1728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brock PR, Koliouskas DE, Barratt TM, et al. Partial reversibility of cisplatin nephrotoxicity in children. J Pediatr 1991; 118:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Georgaki-Angelaki HN, Steed DB, Chantler C, Haycock GB. Renal function following acute renal failure in childhood: a long term follow-up study. Kidney Int 1989; 35:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brenner BM. Nephron adaptation to renal injury or ablation. Am J Physiol 1985; 249:F324.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7231 Version 40.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/856436" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/851939" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The renal pathology in clinical trials of cis-platinum (II) diamminedichloride.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/856437" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28382507" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Cisplatin nephrotoxicity: a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14534679" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Cisplatin and platinum drugs at the molecular level. (Review).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12427549" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The interaction of cisplatin and analogues with DNA in reconstituted chromatin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Plasma levels and organ distribution of platinum in the rat, dog, and dog fish following intravenous administration of cis-DDP (II)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6540826" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Uptake and metabolism of cisplatin by rat kidney.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7193726" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9808712" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17582384" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18559608" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Interaction of Cisplatin with the human organic cation transporter 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18762711" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28689374" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12370430" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19144690" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1316576" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Role of vascular congestion in cisplatin-induced acute renal failure in the rat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4051003" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12235115" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15701814" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10469360" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Protection from toxicant-mediated renal injury in the rat with anti-CD54 antibody.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15814532" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16481417" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : A pathophysiologic role for T lymphocytes in murine acute cisplatin nephrotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12865254" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15569309" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17396112" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17396112" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18656965" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Integrated pathway analysis of rat urine metabolic profiles and kidney transcriptomic profiles to elucidate the systems toxicology of model nephrotoxicants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12506132" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10575556" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Oxidant mechanisms in toxic acute renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11729237" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Manganese superoxide dismutase attenuates Cisplatin-induced renal injury: importance of superoxide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8093036" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Cisplatin generates superoxide anion by interaction with DNA in a cell-free system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9952318" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Reduced sensitivity of HeLa cells to cis-platinum by simultaneous overexpression of copper, zinc-superoxide dismutase and catalase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9363840" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Protective effects of vitamin E and C on cisplatin nephrotoxicity in developing rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8967349" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/733940" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Amelioration of cis-platinum nephrotoxicity by orgotein (superoxide dismutase).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12218054" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Protein kinase C-alpha and ERK1/2 mediate mitochondrial dysfunction, decreases in active Na+ transport, and cisplatin-induced apoptosis in renal cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16672910" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Metabolomic study of cisplatin-induced nephrotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10454078" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Hyperlipidaemia in cisplatin-induced nephrotic rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14612380" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : PPAR alpha ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16316343" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Fibrate prevents cisplatin-induced proximal tubule cell death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17495861" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : A role of liver fatty acid-binding protein in cisplatin-induced acute renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3806171" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10597214" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Platinum organ toxicity and possible prevention in patients with testicular cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7911158" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8683243" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12698184" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11533095" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29320311" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Development and Validation of a Risk Prediction Model for Acute Kidney Injury After the First Course of Cisplatin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23411430" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Long-term nephrotoxicity in adult survivors of childhood cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11316845" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Cisplatin decreases the abundance of aquaporin water channels in rat kidney.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21146122" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/59332" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Combination chemothereapy with cis-diamminedichloroplatinum (II) and bleomycin in tumors of the head and neck.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27073199" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Long-Term Renal Outcomes after Cisplatin Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32383745" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Epidemiologic Characteristics of Acute Kidney Injury During Cisplatin Infusions in Children Treated for Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/375794" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3752072" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1987306" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Chronic hypomagnesemia caused by cisplatin: effect of calcitriol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15947931" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Magnesium depletion enhances cisplatin-induced nephrotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6765498" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Glucose intolerance following cis-platinum treatment in rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6349015" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : The effects of cisplatin and other divalent platinum compounds on glucose metabolism and pancreatic endocrine function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15253918" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9761357" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2986064" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Cis-platinum and distal renal tubule toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3337511" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Renal salt wasting in patients treated with cisplatin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12151962" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Renal salt-wasting syndrome in a patient with cisplatin-induced hyponatremia: case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20622742" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Cisplatin-induced renal salt wasting syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24422172" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Cisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of CD46 treated with eculizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6203452" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11528253" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Chemotherapy-related hemolytic-uremic syndrome following treatment of a carcinoma of the nasopharynx.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31479879" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : A case of primary lung squamous cell carcinoma mimicking malignant mesothelioma producing granulocyte colony stimulating factor with chemotherapy (cisplatin and gemcitabine)-associated thrombotic thrombocytopenic purpura (TTP); An autopsy case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7706473" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Cisplatin-associated anemia: an erythropoietin deficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9225947" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28438887" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34953401" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Preloading magnesium attenuates cisplatin-associated nephrotoxicity: pilot randomized controlled trial (PRAGMATIC study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/415836" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Nephrotoxicity of cis-platinum (II) dichlorodiammine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35436142" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : The Effect of Intravenous Mannitol Combined With Normal Saline in Preventing Cisplatin-Induced Nephrotoxicity: A Randomized, Double-Blind, Placebo-Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32862356" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Effect of mannitol on acute kidney injury induced by cisplatin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35413808" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The effect of mannitol addition to hydration on acute kidney injury event after high dose cisplatin chemotherapy: an ambispective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10363072" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Protection of normal tissues from radiation and cytotoxic therapy: the development of amifostine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10348264" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12065567" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19018081" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3538860" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6890785" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Intraperitoneal cisplatin with systemic thiosulfate protection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15496615" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2758217" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Effect of aminophylline on cisplatin nephrotoxicity in the rat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15590762" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8315935" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Glycine reduces early renal parenchymal uptake of cisplatin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22733767" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25848011" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24408869" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Delayed administration of a single dose of lithium promotes recovery from AKI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7872368" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Treatment of idiopathic renal magnesium wasting with amiloride.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2460594" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2007926" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Partial reversibility of cisplatin nephrotoxicity in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2709664" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Renal function following acute renal failure in childhood: a long term follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3898871" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Nephron adaptation to renal injury or ablation.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
